Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 15/20 | 0.84 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.84 |
| ▸ | MAOB | P27338 | 3/20 | 0.78 |
| ▸ | MAOA | P21397 | 2/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551815 | 1.00 | MIF (0.84) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL551814 | 1.00 | MIF (0.84) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5725630 | 0.91 | MIF (1.00) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5726552 | 0.87 | MIF (0.86) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5724962 | 0.86 | MIF (0.84) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5724535 | 0.86 | MIF (1.00) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL22105155 | 0.86 | MIF (0.66) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL20809674 | 0.84 | MIF (0.80) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5726517 | 0.83 | MIF (0.79) | MIFCYP26A1MAOBMAOACYP19A1 | |
| SCHEMBL5724942 | 0.83 | MIF (1.00) | MIFCYP26A1MAOBMAOACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | MIF 4600/4885CYP26A1 1405/4885MAOB 134/4885 |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | MIF 4600/4885CYP26A1 1405/4885MAOB 134/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | MIF 3183/4885CYP26A1 149/4885MAOB 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.